Acute coronary syndrome
Conditions
Interventions
Conventional Treatment Group:Empirically guided antiplatelet therapy
Precision Treatment Group :Developing an individualized treatment regimen based on the established predictive model, genotypes, and clinical data
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old, gender is not limited; 2. Admitted to the hospital with a diagnosis of acute coronary syndrome or percutaneous coronary artery stent implantation, of which the acute coronary syndrome includes unstable angina, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and other types (clearly diagnosed according to the definition of the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes (ACS); 3. Patients need antiplatelet therapy; 4. Have not started antiplatelet drugs or stopped antiplatelet drugs for more than 1 week at the time of recruitment (such as aspirin, clopidogrel, ticagrelor, etc.); 5. Patients voluntarily participate in this study and agree to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe hepatic dysfunction (Child-Pugh grade B or C and cirrhosis) or severe renal insufficiency (estimated glomerular filtration rate [eGFR] < 30ml/minx1.73m2); 2. Oral anticoagulant drugs (such as warfarin, dabigatran, rivaroxaban, apixaban, etc.); 3. Have serious comorbidities, such as malignant tumors or severe immune system diseases, severe anemia; 4. Pregnant or lactating women and women with pregnancy plans; 5. Life expectancy< 12 months; 6. Known contraindications to oral antiplatelet agents such as aspirin, clopidogrel, ticagrelor, etc., including hypersensitivity reactions, active bleeding, history of intracranial and gastrointestinal bleeding within the past 6 months, and any major surgery within the past 30 days; 7. Interventionist patients who are undergoing other clinical trials or studies; 8. Those with a history of uncontrolled epilepsy, central nervous system disease, or psychiatric disorder, whose clinical severity may preclude the signing of the informed consent form or affect the patient's compliance with oral medications, as judged by the investigator. 9. Life expectancy is less than 1 year; 10. Is using medications with significant drug interactions with antiplatelet agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite Endpoint of Hemorrhagic and Ischemic Events: Hemorrhagic events are defined as any bleeding event meeting the criteria for BARC types 2, 3, or 5, or ISTH-defined major bleeding, clinically relevant non-major bleeding, and minor bleeding; ischemic events include ischemic stroke, systemic embolism, myocardial infarction, stent thrombosis, in-stent restenosis, and unplanned revascularization, as well as cardiac death.; | — |
Countries
China
Contacts
Public ContactYuqi Liu
Chinese PLA General Hospital
Outcome results
None listed